More on The Success Matrix

Gerry Langeler, author of The Success Matrix and Managing Director with OVP Venture Partners recently spoke at a breakfast event and was kind enough to record the video. Gerry’s thoughts on ‘Why scientists fail as entrepreneurs‘ was previously featured on the BiotechBlog, and his video is posted below. For more, you can also visit Gerry’s website at www.thesuccessmatrix.com.  


Key Elements of Succession Planning In Bioscience

This is a guest post from Steve McLaughlin, Managing Partner and Founder of US BioSearch. Do you have a response to Steve’s post? Respond in the comments section below. Effective succession plans involve a combination of many choices and decisions that are distinctive to each, specific company. Bioscience companies also present their own, unique challenges, as […]


The legal and ethical considerations relating to the supply and use of human tissue for biomedical research: A UK perpective

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The legal and ethical considerations relating to the supply and use of human tissue for biomedical research: A UK perpective
Go to paperABSTRACT: Alder H…


Building Biotechnology in Poland

I will be presenting at Bioinnovation 2014 in Gdansk, Poland on October 20-21st. My talk will cover entrepreneurship and business development guidance from my textbook, Building Biotechnology and global competitiveness considerations from my global biotechnology ranking for Scientific American Worldview. I look forward to meeting European and Polish biotechnology practitioners, and learning more about biotechnology […]


Maintaining your independence in biotechnology

Mergers and acquisitions are regular events for biotechnology companies. I have often been asked if being acquired is a goal for biotechnology companies, and if it is seen as a ‘good’ or a ‘bad’ thing. The outlook on merging with another company, or being acquired, is really just a matter of timing. As I describe […]


Patient access to innovation: Biopharmaceuticals, 4th hurdles and socioeconomic issues

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Patient access to innovation: Biopharmaceuticals, 4th hurdles and socioeconomic issues
Go to paperABSTRACT: Biopharmaceuticals and innovative therapeutic…